These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

616 related articles for article (PubMed ID: 36073783)

  • 21. Screening for germline mutations of MLH1, MSH2, MSH6 and PMS2 genes in Slovenian colorectal cancer patients: implications for a population specific detection strategy of Lynch syndrome.
    Berginc G; Bracko M; Ravnik-Glavac M; Glavac D
    Fam Cancer; 2009; 8(4):421-9. PubMed ID: 19526325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Isolated Loss of PMS2 Immunohistochemical Expression is Frequently Caused by Heterogenous MLH1 Promoter Hypermethylation in Lynch Syndrome Screening for Endometrial Cancer Patients.
    Kato A; Sato N; Sugawara T; Takahashi K; Kito M; Makino K; Sato T; Shimizu D; Shirasawa H; Miura H; Sato W; Kumazawa Y; Sato A; Kumagai J; Terada Y
    Am J Surg Pathol; 2016 Jun; 40(6):770-6. PubMed ID: 26848797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics.
    Lagerstedt Robinson K; Liu T; Vandrovcova J; Halvarsson B; Clendenning M; Frebourg T; Papadopoulos N; Kinzler KW; Vogelstein B; Peltomäki P; Kolodner RD; Nilbert M; Lindblom A
    J Natl Cancer Inst; 2007 Feb; 99(4):291-9. PubMed ID: 17312306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Loss of MSH2 and MSH6 due to heterozygous germline defects in MSH3 and MSH6.
    Morak M; Käsbauer S; Kerscher M; Laner A; Nissen AM; Benet-Pagès A; Schackert HK; Keller G; Massdorf T; Holinski-Feder E
    Fam Cancer; 2017 Oct; 16(4):491-500. PubMed ID: 28528517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Associations of Pathogenic Variants in MLH1, MSH2, and MSH6 With Risk of Colorectal Adenomas and Tumors and With Somatic Mutations in Patients With Lynch Syndrome.
    Engel C; Ahadova A; Seppälä TT; Aretz S; Bigirwamungu-Bargeman M; Bläker H; Bucksch K; Büttner R; de Vos Tot Nederveen Cappel WT; Endris V; Holinski-Feder E; Holzapfel S; Hüneburg R; Jacobs MAJM; Koornstra JJ; Langers AM; Lepistö A; Morak M; Möslein G; Peltomäki P; Pylvänäinen K; Rahner N; Renkonen-Sinisalo L; Schulmann K; Steinke-Lange V; Stenzinger A; Strassburg CP; van de Meeberg PC; van Kouwen M; van Leerdam M; Vangala DB; Vecht J; Verhulst ML; von Knebel Doeberitz M; Weitz J; Zachariae S; Loeffler M; Mecklin JP; Kloor M; Vasen HF; ;
    Gastroenterology; 2020 Apr; 158(5):1326-1333. PubMed ID: 31926173
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lynch syndrome caused by a novel deletion of the promoter and exons 1-13 of MLH1 gene.
    Huang J; Stinnett V; Jiang L; Chen S; Rodriguez F; Gocke CD; Zou YS
    Cancer Genet; 2022 Apr; 262-263():91-94. PubMed ID: 35149321
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MLH1 intronic variants mapping to + 5 position of splice donor sites lead to deleterious effects on RNA splicing.
    Piñero TA; Soukarieh O; Rolain M; Alvarez K; López-Köstner F; Torrezan GT; Carraro DM; De Oliveira Nascimento IL; Bomfim TF; Machado-Lopes TMB; Freitas JC; Toralles MB; Sandes KA; Rossi BM; Junior SA; Meira J; Dominguez-Valentin M; Møller P; Vaccaro CA; Martins A; Pavicic WH
    Fam Cancer; 2020 Oct; 19(4):323-336. PubMed ID: 32363481
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence of CNV-neutral structural genomic rearrangements in MLH1, MSH2, and PMS2 not detectable in routine NGS diagnostics.
    Morak M; Steinke-Lange V; Massdorf T; Benet-Pages A; Locher M; Laner A; Kayser K; Aretz S; Holinski-Feder E
    Fam Cancer; 2020 Apr; 19(2):161-167. PubMed ID: 32002723
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MSH6 and PMS2 germ-line pathogenic variants implicated in Lynch syndrome are associated with breast cancer.
    Roberts ME; Jackson SA; Susswein LR; Zeinomar N; Ma X; Marshall ML; Stettner AR; Milewski B; Xu Z; Solomon BD; Terry MB; Hruska KS; Klein RT; Chung WK
    Genet Med; 2018 Oct; 20(10):1167-1174. PubMed ID: 29345684
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multigene Panel Testing Provides a New Perspective on Lynch Syndrome.
    Espenschied CR; LaDuca H; Li S; McFarland R; Gau CL; Hampel H
    J Clin Oncol; 2017 Aug; 35(22):2568-2575. PubMed ID: 28514183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Screening for germline mutations in mismatch repair genes in patients with Lynch syndrome by next generation sequencing.
    Soares BL; Brant AC; Gomes R; Pastor T; Schneider NB; Ribeiro-Dos-Santos Â; de Assumpção PP; Achatz MIW; Ashton-Prolla P; Moreira MAM
    Fam Cancer; 2018 Jul; 17(3):387-394. PubMed ID: 28932927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gene-Specific Variation in Colorectal Cancer Surveillance Strategies for Lynch Syndrome.
    Kastrinos F; Ingram MA; Silver ER; Oh A; Laszkowska M; Rustgi AK; Hur C
    Gastroenterology; 2021 Aug; 161(2):453-462.e15. PubMed ID: 33839100
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Implication of DNA repair genes in Lynch-like syndrome.
    Xicola RM; Clark JR; Carroll T; Alvikas J; Marwaha P; Regan MR; Lopez-Giraldez F; Choi J; Emmadi R; Alagiozian-Angelova V; Kupfer SS; Ellis NA; Llor X
    Fam Cancer; 2019 Jul; 18(3):331-342. PubMed ID: 30989425
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Screening for Lynch syndrome in young Saudi colorectal cancer patients using microsatellite instability testing and next generation sequencing.
    Alqahtani M; Edwards C; Buzzacott N; Carpenter K; Alsaleh K; Alsheikh A; Abozeed W; Mashhour M; Almousa A; Housawi Y; Al Hawwaj S; Iacopetta B
    Fam Cancer; 2018 Apr; 17(2):197-203. PubMed ID: 28643016
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Universal Lynch Syndrome Screening Should be Performed in All Upper Tract Urothelial Carcinomas.
    Ju JY; Mills AM; Mahadevan MS; Fan J; Culp SH; Thomas MH; Cathro HP
    Am J Surg Pathol; 2018 Nov; 42(11):1549-1555. PubMed ID: 30148743
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of screening strategies for Lynch syndrome in patients with newly diagnosed endometrial cancer: a prospective cohort study in China.
    Chao X; Li L; Wu M; Ma S; Tan X; Zhong S; Bi Y; Lang J
    Cancer Commun (Lond); 2019 Jul; 39(1):42. PubMed ID: 31307542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer Risk C (CR-C), a functional genomics test is a sensitive and rapid test for germline mismatch repair deficiency.
    Alim I; Loke J; Yam S; Templeton AS; Newcomb P; Lindor NM; Pai RK; Jenkins MA; Buchanan DD; Gallinger S; Klugman S; Ostrer H
    Genet Med; 2022 Sep; 24(9):1821-1830. PubMed ID: 35616648
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Expression and clinical significance of MMR protein and MLH1 promoter methylation testing in endometrial cancer].
    Jin W; Wang LQ; Liu Y; Liu AJ
    Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):823-830. PubMed ID: 30585020
    [No Abstract]   [Full Text] [Related]  

  • 39. Molecular and Clinicopathologic Characterization of Mismatch Repair-Deficient Endometrial Carcinoma Not Related to MLH1 Promoter Hypermethylation.
    Kaya M; Post CCB; Tops CM; Nielsen M; Crosbie EJ; Leary A; Mileshkin LR; Han K; Bessette P; de Boer SM; Jürgenliemk-Schulz IM; Lutgens L; Jobsen JJ; Haverkort MAD; Nout RA; Kroep J; Creutzberg CL; Smit VTHBM; Horeweg N; van Wezel T; Bosse T
    Mod Pathol; 2024 Mar; 37(3):100423. PubMed ID: 38191122
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of germline mutations of MLH1 and MSH2 in unrelated south American suspected Lynch syndrome individuals.
    Valentin MD; da Silva FC; dos Santos EM; Lisboa BG; de Oliveira LP; Ferreira Fde O; Gomy I; Nakagawa WT; Aguiar Junior S; Redal M; Vaccaro C; Valle AD; Sarroca C; Carraro DM; Rossi BM
    Fam Cancer; 2011 Dec; 10(4):641-7. PubMed ID: 21681552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.